Christopher L. Bowlus

Feb 21, 2024 | nejm.org | Christopher L. Bowlus |Andreas Kremer |John M. Vierling |Kris V. Kowdley

February 29, 2024N Engl J Med 2024; 390:783-794 DOI: 10.1056/NEJMoa2312100 AbstractEffective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits.

Nov 13, 2023 | nejm.org | Kris V. Kowdley |Christopher L. Bowlus |Cynthia Levy |Mario Alvares-da-Silva

November 13, 2023 DOI: 10.1056/NEJMoa2306185 AbstractPrimary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.

Nov 13, 2023 | nejm.org | Kris V. Kowdley |Christopher L. Bowlus |Cynthia Levy |Mario Alvares-da-Silva

AbstractPrimary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.

Jun 13, 2023 | giejournal.org | Lars Aabakken |Christopher L. Bowlus |Douglas G. Adler |Joyce Peetermans

Cookie Preference CenterWe use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.